Quantcast

Gallus Announces Completion of $5 Million Process Development Expansion for Biologics Contract Manufacturing

January 29, 2014

Gallus BioPharmaceuticals, a premier pure-play biologics contract manufacturing organization, has completed a second expansion of its Process Development facility at its headquarters in St. Louis, Missouri. This expansion provides additional laboratory space and state-of-the-art instrumentation to support Gallus’ growth and commitment to leading pharma and biotech clients in the development of new biotherapeutics.

St. Louis, Missouri (PRWEB) January 29, 2014

Gallus BioPharmaceuticals, LLC (Gallus), a premier pure-play biologics contract manufacturing organization (CMO), has completed a second expansion of its Process Development (PD) facility at its headquarters in St. Louis, Missouri. This expansion provides additional laboratory space and state-of-the-art instrumentation to support Gallus’ growth and commitment to leading pharma and biotech clients in the development of new biotherapeutics.

Mark R. Bamforth, Gallus’ President and CEO, stated, “Following the acquisition of the Laureate Biopharma business last September, Gallus is now supporting 5 of the top 15 pharmaceutical companies and a growing number of emerging and mid-sized biotechs in bringing new molecules to the clinic. This additional investment increases Gallus’ capacity to serve our clients’ needs with our team of over 70 Process Development scientists. We’ve designed the new integrated PD labs to facilitate collaborative and efficient development and tech transfer of processes. The design allows our Process Development team flexibility in adjusting for project specific configurations as needed.”

The expansion includes the addition of the state-of-the-art ambr™ System from TAP Biosystems, a high throughput system designed for microscale clone and media selection and bioreactor process optimization. This addition is in response to the rapidly growing need for optimizing the yields and purity of complex biotherapeutic molecules. “The ambr™ high-throughput mini-bioreactor system allows Gallus to develop robust, high-producing cell culture processes for our clients while reducing time lines and meeting regulatory expectations,” stated Matt Caple, Director of Cell Culture Development at Gallus.

About Gallus BioPharmaceuticals

Gallus BioPharmaceuticals is a leading contract manufacturing company offering exceptional contract services to its clients. Gallus’ world-class facility in St. Louis is distinguished by nearly three decades of biologics development and over a decade of commercial cGMP manufacturing, including the ongoing manufacture of Stelara® and Remicade® for Janssen Pharmaceuticals. Gallus’ facility in Princeton, New Jersey, has three decades of experience in process development and clinical manufacturing of bulk and aseptic-filling of mAbs, as well as large and complex proteins such as Fc-fusion proteins, IgMs, and collagens, plus over 15 years of experience in commercial manufacture of ProstaScint®. Both sites maintain exemplary quality and regulatory records.

For additional information, visit http://www.gallusbiopharma.com or email: info(at)gallusbiopharma(dot)com.

Contact information:

Gallus BioPharmaceuticals, LLC

Claire Ruzicka, Sr. Marketing Manager

4766 LaGuardia Drive, St. Louis, MO 63134-3117

+1.314.562.5755

claire.ruzicka(at)gallusbiopharma(dot)com

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/01/prweb11529423.htm


Source: prweb



comments powered by Disqus